What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Platelet function testing (n=105). Intervention: PFA-100. Primary outcome: Laboratory usage of the PFA-100.

What question did this study set out to answer?

This audit aims to evaluate the usage of the PFA-100 as a screening tool for platelet function and its effectiveness amidst various platelet disorders.

June 20, 2007Blood Coagulation & Fibrinolysis

Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand

View Full Paper

Ask AI

Bookmark

Key result

Among 105 surveyed laboratories, 26 (65% of those performing platelet function testing) utilized the PFA-100, with wide variation in usage and most abnormal findings attributed to aspirin.

Population

105 haemostasis laboratories participating in the Royal College of Pathologists of Australasia Quality…

Design

Cross-sectional

Authors

EFEmmanuel J. FavaloroVascular Medicine RBRoslyn BonarRoyal College of Pathologists of Australasia EDElizabeth M. DuncanUniversity of Kentucky

Discussion

Member takes

Implication

Variation in PFA-100 use warrants interpretive caution; leaves open need for standardization studies.

Key Points

This audit aims to evaluate the usage of the PFA-100 as a screening tool for platelet function and its effectiveness amidst various platelet disorders.
Surveyed 105 laboratories under the Royal College of Pathologists of Australasia Quality Assurance Program.
40 laboratories performed platelet function testing, with 26 (65%) utilizing the PFA-100.
Collected data on testing criteria, sources of requests, and follow-up actions.
Laboratories reported a median of 270 PFA-100 tests annually, with a range of 15 to 6000 tests.
Most tests were completed within 4 hours of collection, as recommended by the manufacturer.
Abnormal findings were primarily linked to antiplatelet medications like aspirin.

Study Design

Type

Cross-Sectional (n=105)

Multicenter

Yes

Structured PICO

Population

105 haemostasis laboratories in Australia and New Zealand surveyed regarding their usage of the PFA-100 for platelet function testing.

Exposure

Audit/survey of PFA-100 usage for platelet function testing

Outcome

Laboratory usage patterns of PFA-100 (numbers of tests, sources of requests, testing criteria, and follow-up action)

There is wide variation in the laboratory usage of the PFA-100 for platelet function screening across Australia and New Zealand, with most abnormal results attributed to antiplatelet medications.

Cite This Study

Favaloro et al. (2007) conducted a cross-sectional in Platelet function testing (n=105). PFA-100 was evaluated on Laboratory usage of the PFA-100. Among 105 surveyed laboratories, 26 (65% of those performing platelet function testing) utilized the PFA-100, with wide variation in usage and most abnormal findings attributed to aspirin.

synapsesocial.com/papers/6a6ac166547974b2dbf41ef7 https://doi.org/10.1097/mbc.0b013e328136c178

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Topics

Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider